Fremanezumab for preventive treatment of migraine

Functional status on headache-free days

Juliana VanderPluym, David W. Dodick, Richard B. Lipton, Yuju Ma, Pippa S. Loupe, Marcelo E. Bigal

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.

METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89).

RESULTS: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab.

CONCLUSION: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).

CLINICALTRIALSGOV IDENTIFIER: NCT02025556 and NCT02021773.

CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.

Original languageEnglish (US)
Pages (from-to)e1152-e1165
JournalNeurology
Volume91
Issue number12
DOIs
StatePublished - Sep 18 2018

Fingerprint

Migraine Disorders
Headache
Therapeutics
Placebos
Mental Fatigue
Fatigue
Emotions
Prospective Studies
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Fremanezumab for preventive treatment of migraine : Functional status on headache-free days. / VanderPluym, Juliana; Dodick, David W.; Lipton, Richard B.; Ma, Yuju; Loupe, Pippa S.; Bigal, Marcelo E.

In: Neurology, Vol. 91, No. 12, 18.09.2018, p. e1152-e1165.

Research output: Contribution to journalArticle

VanderPluym, Juliana ; Dodick, David W. ; Lipton, Richard B. ; Ma, Yuju ; Loupe, Pippa S. ; Bigal, Marcelo E. / Fremanezumab for preventive treatment of migraine : Functional status on headache-free days. In: Neurology. 2018 ; Vol. 91, No. 12. pp. e1152-e1165.
@article{cdd1e056aa0349fcbea8b5a19ab43d96,
title = "Fremanezumab for preventive treatment of migraine: Functional status on headache-free days",
abstract = "OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89).RESULTS: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab.CONCLUSION: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).CLINICALTRIALSGOV IDENTIFIER: NCT02025556 and NCT02021773.CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.",
author = "Juliana VanderPluym and Dodick, {David W.} and Lipton, {Richard B.} and Yuju Ma and Loupe, {Pippa S.} and Bigal, {Marcelo E.}",
year = "2018",
month = "9",
day = "18",
doi = "10.1212/01.wnl.0000544321.19316.40",
language = "English (US)",
volume = "91",
pages = "e1152--e1165",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Fremanezumab for preventive treatment of migraine

T2 - Functional status on headache-free days

AU - VanderPluym, Juliana

AU - Dodick, David W.

AU - Lipton, Richard B.

AU - Ma, Yuju

AU - Loupe, Pippa S.

AU - Bigal, Marcelo E.

PY - 2018/9/18

Y1 - 2018/9/18

N2 - OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89).RESULTS: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab.CONCLUSION: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).CLINICALTRIALSGOV IDENTIFIER: NCT02025556 and NCT02021773.CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.

AB - OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue. Individuals with EM receiving monthly doses of fremanezumab 225 mg (n = 96) or 675 mg (n = 97) or placebo (n = 104) were compared. Individuals with CM receiving fremanezumab 675 mg followed by monthly 225 mg (n = 88) and 900 mg (n = 86) were also independently compared to those receiving placebo (n = 89).RESULTS: In patients with EM, compared to patients receiving placebo, those receiving fremanezumab experienced an increased number of headache-free days with normal function in work/school/household chore performance and concentration/mental fatigue measures compared to their baseline over the entire treatment period (all p < 0.005). An increased number of headache-free days with normal functional performance for some measures was also found in the CM group in those treated with fremanezumab.CONCLUSION: There was an increased number of headache-free days with normal functional performance on all measures for the patients with EM and some measures for patients with CM in the fremanezumab-treated groups. Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).CLINICALTRIALSGOV IDENTIFIER: NCT02025556 and NCT02021773.CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.

UR - http://www.scopus.com/inward/record.url?scp=85054083264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054083264&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000544321.19316.40

DO - 10.1212/01.wnl.0000544321.19316.40

M3 - Article

VL - 91

SP - e1152-e1165

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -